It has been reported that India's indigenously-developed Bharat Biotech's vaccine- Covaxin is witnessing a shortage of volunteer participation for the phase III clinical trial.Dr Sanjay Rai, Professor of Community Medicine at AIIMS told that "When the clinical trial began, we wanted 100 volunteers and received over 4,500 applications.
In phase II, we wanted 50 and received 4000 applications. In phase III, now when wanted 1,500-2,000 participants, we could only recruit about 200 participants as of now. It is happening because people are thinking about why to volunteer when a vaccine is coming for everyone soon.
"He added that "even if a vaccine comes, it'll be given to healthcare providers, frontline workers, elderly with co-morbidities first. But people think they will get vaccine soon".